These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24657718)

  • 1. Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice.
    Takei S; Omoto C; Kitagawa K; Morishita N; Katayama T; Shigemura K; Fujisawa M; Kawabata M; Hotta H; Shirakawa T
    Vaccine; 2014 May; 32(25):3066-74. PubMed ID: 24657718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-α, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice.
    Kitagawa K; Omoto C; Oda T; Araki A; Saito H; Shigemura K; Katayama T; Hotta H; Shirakawa T
    Viral Immunol; 2017 Apr; 30(3):196-203. PubMed ID: 28112593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadening CD4
    Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo.
    Gao M; Wang HP; Wang YN; Zhou Y; Wang QL
    Vaccine; 2006 Jun; 24(26):5491-7. PubMed ID: 16725235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The combined application of nucleotide and amino acid sequences of NS3 hepatitis C virus protein, DNA encoding granulocyte macrophage colony-stimulating factor and inhibitor of regulatory T cells induces effective immune response against hepatitis C virus].
    Masalova OV; Lesnova EI; Shingarova LN; Tunitskaia VL; Ulanova TI; Burkov AN; Kushch AA
    Mol Biol (Mosk); 2012; 46(3):525-34. PubMed ID: 22888642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.
    Jin B; Wang RY; Qiu Q; Sugauchi F; Grandinetti T; Alter HJ; Shih JW
    Immunology; 2007 Sep; 122(1):15-27. PubMed ID: 17451465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation.
    Martinez-Donato G; Amador-Cañizares Y; Alvarez-Lajonchere L; Guerra I; Pérez A; Dubuisson J; Wychowsk C; Musacchio A; Aguilar D; Dueñas-Carrera S
    Vaccine; 2014 Mar; 32(15):1720-6. PubMed ID: 24486345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.
    Echeverria I; Pereboev A; Silva L; Zabaleta A; Riezu-Boj JI; Bes M; Cubero M; Borras-Cuesta F; Lasarte JJ; Esteban JI; Prieto J; Sarobe P
    Hepatology; 2011 Jul; 54(1):28-37. PubMed ID: 21452282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.
    Haller AA; Lauer GM; King TH; Kemmler C; Fiolkoski V; Lu Y; Bellgrau D; Rodell TC; Apelian D; Franzusoff A; Duke RC
    Vaccine; 2007 Feb; 25(8):1452-63. PubMed ID: 17098335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus-specific cellular and humoral immune responses following immunization with a multi-epitope fusion protein.
    Qiu F; Bi S; Wang Y; Guo M; Yi Y; Chen S; Guo Y; Shen L; Jia Z
    Int J Mol Med; 2012 Jan; 29(1):12-7. PubMed ID: 21956746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
    El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
    J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
    Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
    Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.
    Gummow J; Li Y; Yu W; Garrod T; Wijesundara D; Brennan AJ; Mullick R; Voskoboinik I; Grubor-Bauk B; Gowans EJ
    J Virol; 2015 Aug; 89(15):7991-8002. PubMed ID: 26018154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities.
    Ratnoglik SL; Jiang DP; Aoki C; Sudarmono P; Shoji I; Deng L; Hotta H
    PLoS One; 2014; 9(6):e98877. PubMed ID: 24901478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy.
    Li W; Krishnadas DK; Li J; Tyrrell DL; Agrawal B
    J Immunol; 2006 May; 176(10):6065-75. PubMed ID: 16670315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.
    Smyk-Pearson S; Tester IA; Lezotte D; Sasaki AW; Lewinsohn DM; Rosen HR
    J Infect Dis; 2006 Aug; 194(4):454-63. PubMed ID: 16845628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.